Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Auto industry rebound could drive these under $10 stocks

The unpopular trade I told you about one month ago – to go long homebuilding stocks – is off to a great start. The big homebuilder fund ( XHB ) is up around 8% so far, and just hit a new yearly high. Today, I have another trade most people will think is crazy, whi...
Frank Curzio | October 28, 2012 |

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also anno...
Streetwise Reports | October 23, 2019 |

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. This...
Streetwise Reports | January 9, 2020 |

Buzz on the Bullboards: Volatility persists in the face of economic indicators

This week has proven to be a challenging one for investors on both sides of the border. Canada’s main stock index struggled to gain traction as Statistics Canada reported another rise in the Industrial Product Price Index for April, reflecting ongoing...
Jonathon Brown | 2 days ago |

Voxtur is the Leading Provider of Digital, SaaS Solutions for Real Estate Transactions in N. America

Before we dive into what makes Voxtur Analytics ( TSX-V: VXTR ; OTCQB: VXTRF) a standout PropTech company (and an undervalued investment opportunity), it’s worth highlighting a few recent developments: –Voxtur has seen revenues increase 300% year-over-year a...
Stockhouse Editorial | September 22, 2021 |

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...
Dave Jackson | January 31, 2022 |

Graphite Miner Faces Hurdles but Foresees Strong Market for Product

Maurice Jackson: Today we will share a graphite development company set for production. Joining us for a conversation is Dan Weir, the executive chairman of DNI Metals Inc. (DNI:CSE; DMNKF:OTC) . Mr. Weir, welcome to the show, sir. Delighted to have you back to provid...
Streetwise Reports | April 1, 2020 |

Fission Uranium: As demand for clean energy grows, so too will the demand for uranium

Many countries across the world, including the United States and its new generation of modular reactors, are more and more looking towards nuclear solution to solve their clean energy problems and accelerate decarbonization. As nuclear energy grows, so too will the d...
Simon Druker | November 4, 2022 |

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. Biopharmaceutical maker Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) yesterday announced financial and ...
Streetwise Reports | August 6, 2019 |

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...
Streetwise Reports | August 14, 2019 |
1 2 3 4 5